News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

12,717 Results

Type

Article (553)
Company Profile (1)
Press Release (12163)

Section

Business (3399)
Career Advice (1)
Deals (826)
Drug Development (1152)
Employer Resources (1)
FDA (246)
Job Trends (118)
News (5747)
Policy (498)

Tag

Date

Last 7 days (2)
Last 30 days (18)
Last 365 days (439)
2025 (27)
2024 (450)
2023 (557)
2022 (1829)
2021 (1629)
2020 (1117)
2019 (743)
2018 (473)
2017 (639)
2016 (518)
2015 (744)
2014 (579)
2013 (492)
2012 (564)
2011 (503)
2010 (429)

Location

Africa (4)
Arizona (1)
Asia (571)
Australia (173)
California (13)
Canada (20)
China (1)
Europe (5190)
Florida (5)
Idaho (1)
Illinois (5)
Japan (4)
Maryland (4)
Massachusetts (27)
Michigan (5)
New Jersey (10)
New York (5)
North Carolina (6)
Northern California (8)
Pennsylvania (38)
South America (17)
Southern California (2)
Texas (2)
Utah (2)
Wisconsin (1)

Filters

Type

Article (553)
Company Profile (1)
Press Release (12163)

Section

Business (3399)
Career Advice (1)
Deals (826)
Drug Development (1152)
Employer Resources (1)
FDA (246)
Job Trends (118)
News (5747)
Policy (498)

Tag

Date

Last 7 days (2)
Last 30 days (18)
Last 365 days (439)
2025 (27)
2024 (450)
2023 (557)
2022 (1829)
2021 (1629)
2020 (1117)
2019 (743)
2018 (473)
2017 (639)
2016 (518)
2015 (744)
2014 (579)
2013 (492)
2012 (564)
2011 (503)
2010 (429)

Location

Africa (4)
Arizona (1)
Asia (571)
Australia (173)
California (13)
Canada (20)
China (1)
Europe (5190)
Florida (5)
Idaho (1)
Illinois (5)
Japan (4)
Maryland (4)
Massachusetts (27)
Michigan (5)
New Jersey (10)
New York (5)
North Carolina (6)
Northern California (8)
Pennsylvania (38)
South America (17)
Southern California (2)
Texas (2)
Utah (2)
Wisconsin (1)

12,717 Results for "novaliq gmbh".

Sort By

Press Releases

Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

October 2, 2024
·
5 min read
Policy

European Medicines Agency Accepts Novaliq’s Marketing Authorization Application for CyclASol® (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency has accepted the marketing authorization application for CyclASol for regulatory review.

August 24, 2023
·
3 min read
Deals

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

Harrow (Nasdaq: HROW) and Novaliq GmbH today announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.

July 18, 2023
·
11 min read
FDA

Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

June 8, 2023
·
5 min read
Business

Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

June 13, 2023
·
5 min read
Genetown

CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Senju Pharmaceutical Co., Ltd. and Novaliq GmbH are pleased to announce the closing of a license agreement on Japan rights to develop, manufacture, and commercialize NOV03, the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.

June 13, 2023
·
5 min read
Press Releases

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH

January 14, 2025
·
3 min read
FDA

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”)and Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED).

May 18, 2023
·
9 min read
Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024
·
3 min read
Business

Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH

Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.

April 9, 2024
·
2 min read

1 of 1,272

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin